Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation

Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation

With the development of sequencing technology, the detection rate of de novo T790M mutation is increasing. The emergence of the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide treatment opportunities. Secondary T790M mutation is often emphasized...

Full description

Bibliographic Details
Main Authors:	Xin WANG, Diansheng ZHONG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-05-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms Epidermal growth factor receptor (EGFR) T790M
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.10

Similar Items

Advanced Research on T790M Mutation in Non-small Cell Lung Cancer
by: Hui LI, et al.
Published: (2013-06-01)

Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review
by: Xue YANG, et al.
Published: (2023-02-01)

Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
by: Eun Hye Lee, et al.
Published: (2024-08-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

TKI Resistance for T790M Mutation
by: Hong WANG, et al.
Published: (2015-04-01)

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
by: Wen-Chien Cheng, et al.
Published: (2022-12-01)

Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2018-09-01)

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
by: Jianxin Chen, et al.
Published: (2022-07-01)

EGFR T790M: revealing the secrets of a gatekeeper
by: Ko B, et al.
Published: (2017-10-01)

Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer
by: Qin YU, et al.
Published: (2017-03-01)

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
by: LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan
Published: (2024-04-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
by: Naoki Haratake, MD, PhD, et al.
Published: (2020-11-01)

Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
by: Minehiko Inomata, et al.
Published: (2020-11-01)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
by: Chihiro Maeda, et al.
Published: (2023-10-01)

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients
by: Hui Zhang, et al.
Published: (2023-01-01)

Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer
by: Caitriona Goggin, et al.
Published: (2021-12-01)

Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
by: Xiaohuang Yang, et al.
Published: (2022-07-01)

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
by: Xiao-Fang Yi, et al.
Published: (2022-06-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
by: Yoshiya Matsumoto, et al.
Published: (2022-07-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
by: Tadashi Nishimura, et al.
Published: (2021-04-01)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
by: Yue Fang, et al.
Published: (2023-01-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2018-01-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01)

Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma
by: Xiumei Li, et al.
Published: (2023-09-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024-03-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
by: Shinichi Miyazaki, et al.
Published: (2020-08-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer
by: Yaoyao LIU, et al.
Published: (2023-12-01)